This CME/CE activity will highlight novel treatment strategies for sphingosine-1-phosphate (S1P) therapeutics to manage patients with moderate to severe ulcerative colitis (UC). The expert faculty, led by Dr. David T. Rubin, will first review the need for new therapeutics in ulcerative colitis, including treatment goals and unmet needs. Next, the faculty will analyze the science of S1P receptor modulators as a therapeutic option for the treatment of UC, along with assessing recent clinical trial data on the safety and efficacy of these novel S1P therapeutics. The faculty will then review treatment and communication strategies for patients with UC. To conclude, the faculty will hold an interactive panel discussion, delving into sphingosine-1-phosphate therapeutics as a way improve outcomes in patients with ulcerative colitis.
Gastroenterologists, gastroenterology nurses and other healthcare professionals who manage patients with inflammatory bowel disease
- Review the science of sphingosine-1-phosphate (S1P) receptor modulators as a therapeutic option for the treatment and management of ulcerative colitis.
- Analyze the most recent clinical trial data on the efficacy and safety of novel sphingosine-1- phosphate (S1P) therapeutics for the treatment of UC.
- Update treatment strategies to apply novel therapeutics to treat patients with moderate to severe ulcerative colitis.
I. Why Do We Need New Therapeutics in Ulcerative Colitis? – David T. Rubin, MD
II. Sphingosine-1-Phosphate Science as a Therapeutic Target for Ulcerative Colitis – Jessica R. Allegretti, MD
III. Clinical Trial Analysis for Novel S1P Treatment for Moderate to Severe Ulcerative Colitis – David T. Rubin, MD
IV. Enhanced Communication Strategies for Patients with UC – Sarah O’Rourke, DNP, RN
V. Faculty Panel Discussion –All Faculty
Jessica R. Allegretti, MD, MPH, FACG
Associate Director, Crohn’s and Colitis Center
Director, Fecal Microbiota Transplant Program
Division of Gastroenterology, Brigham and Women’s Hospital
Harvard Medical School
Sarah O’Rourke, DNP, RN
University of Chicago
Digestive Diseases Center
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|David T. Rubin, MD||Consultant/Advisor: AbbVie Inc.; Altrubio; Allergan; Arena; Athos Therapeutics; Bellatrix Pharmaceuticals; Boehringer Ingelheim; Bristol Meyers Squibb; Celgene Corp/Syneos; GalenPharma/Atlantica; Genentech USA, Inc.; Gilead Sciences, Inc.; InDex Pharmaceuticals; Ironwood Pharmaceuticals; Iterative Scopes; Janssen Pharmaceuticals, Inc.; Lilly; Materia Prima; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; Takeda Pharmaceutical Company; Techlab, Inc.|
|Jessica R. Allegretti, MD, MPH||Consultant/Advisor: Bristol Meyers Squibb; Finch Therapeutics Group, Inc.; Iterative Scopes, Inc; Janssen Pharmaceuticals, Inc.; Pandion Therapeutics, Inc.; Pfizer Inc.
Grant/Research Support: Merck & Co., Inc
Speaker’s Bureau: Bristol Meyers Squibb
|Sarah O’Rourke, DNP, RN||Nothing to disclose|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour.
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Bristol Myers Squibb
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].